EASD 2026: Oral semaglutide drives weight loss after switch from injectable GLP-1s

Conferencepositiveoral semaglutideinjectable GLP-1sPositive

AI Analysis

Summary

Oral semaglutide demonstrated effective weight loss maintenance when patients switched from injectable GLP-1 therapies, presented at EASD 2026. The findings support oral semaglutide as a viable oral alternative for weight loss management.

Outcome Details

Oral semaglutide maintains weight-loss progress after injectable GLP-1 therapy switch

Importance:5/10

Sentiment:

0.65

obesityGLP-1oral formulationEASD 2026weight lossswitch therapy

Related Companies

$NVO

Read the original article

Published by Clinical Trials Arena on September 30, 2026 7:46 PM

Read Original